SG Americas Securities
SRPT icon

SG Americas Securities’s Sarepta Therapeutics SRPT Stock Holding History

SG Americas Securities’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-22,000
Closed -$308K – 3466
2020
Q3 		$308K Buy
+22,000
New +$3.34M ﹤0.01% 1925

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

SG Americas Securities's SRPT Position: Q2 2026 in Review

SG Americas Securities reduced its Sarepta Therapeutics (SRPT) stake by 67% in Q2 2026, selling an estimated $7.04M and leaving 186,662 shares worth $3.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1266.

SG Americas Securities first reported a position in SRPT in Q3 2013 and has held it in 35 quarters since. The position peaked at $12.2M in Q1 2026. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • SG Americas Securities held 186,662 shares of Sarepta Therapeutics worth $3.35M as of Q2 2026.
  • SG Americas Securities sold 372,401 Sarepta Therapeutics shares in Q2 2026, an estimated $7.04M.
  • Sarepta Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1266 holding.
  • SG Americas Securities first reported a position in Sarepta Therapeutics in Q3 2013 and has held it in 35 quarters since.
  • SG Americas Securities's Sarepta Therapeutics position peaked at $12.2M in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.